DDR1-mediated cell purification of pancreatic endocrine cells through their progenitors

• US 8,551,779 B2
• Filed: 12/19/2008
• Issued: 10/08/2013
• Est. Priority Date: 12/28/2007
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Hald, Jacob, Madsen, Ole Dragsbk, Serup, Palle
• Primary Examiner(s): GITOMER, RALPH J
• Application Number:
  US12/810,960
• Publication Number:
  US 20110014160A1
• Time in Patent Office: 1,754 Days
• Field of Search: 435/366, 435/377
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12N 5/0676 Pancreatic cells
• CPC Class Codes: C12N 5/0678 Stem cells; Progenitor cells; Precursor cells
• CPC Class Codes: G01N 33/507 Pancreatic cells

Abstract

The invention relates to a method of identifying, obtaining and/or quantifying a culture of pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well as sorting such cells. The invention further relates to a selective cell surface marker, DDR1, that permits the selection of a unique subset of cells with pancreatic endocrine progenitor phenotype. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof.

Claims

1. A method of identification of pancreatic cells comprising cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, and early endocrine cells, the method comprising contacting a cell population comprising pancreatic cells with a DDR1 (Discoidin Domain Receptor family, member 1) binding reagent and detecting cells that bind the DDR1 binding reagent.

9. The method of claim 1, wherein the DDR1 binding reagent is an antibody that specifically binds to DDR1.

10. The method of claim 1, wherein the cell population comprises pancreatic cells is selected from the group consisting of a cell population obtained from a pancreas, a somatic cell population, and a cell population obtained from pluripotent cells.

11. The method of claim 10, wherein the pluripotent cells are embryonic stem cells.

12. The method of claim 1, wherein the cell population comprising pancreatic cells is of human origin.

13. The method of claim 12, wherein the cell population comprising pancreatic cells has been differentiated into the pancreatic endocrine lineage.

14. The method of claim 1, wherein the cells are endocrine progenitor cells.

2. A method of obtaining a culture of pancreatic cells comprising cells selected from the group consisting of ductal/endocrine progenitor cells, pancreatic endocrine progenitor cells, and early endocrine cells comprising:

contacting a cell population comprising pancreatic cells with a DDR1 binding reagent and separating the cells that binds bind the DDR1 binding reagent in a fraction of DDR1 positive cells from cells that do not bind the DDR1 binding reagent.

3. The method of claim 2, comprising the subsequent step of culturing the obtained cells under conditions which facilitate their differentiation into pancreatic cells comprising cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells.

4. The method of claim 2, comprising the subsequent step of culturing the obtained cells under conditions which facilitate expansion of the pancreatic cells obtained.

5. The method of claim 4, further comprising the subsequent steps of obtaining the cells after expansion and culturing the obtained cells under conditions which facilitates differentiation of the cells into pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells.

6. The method of providing pancreatic endocrine function to a mammal deficient in its production of at least one pancreatic hormone wherein cells are obtained by the method according to claim 5, the method further comprising the steps of:

implanting into the mammal the obtained cells in an amount sufficient to produce a measurable amount of at least one pancreatic hormone in the mammal.

15. The method of claim 2, wherein the DDR1 positive cells are further differentiated into insulin producing cells.

16. The method of claim 2, wherein the DDR1 positive cells are further differentiated into insulin producing cells and at least one of glucagon producing cells, somatostatin producing cells, pancreatic polypeptide producing cells or ghrelin producing cells.

17. The method of claim 3, wherein the pancreatic endocrine cells obtained is further separated in a beta cell-positive fraction.

7. A method of quantifying DDR1 positive cells in an in vitro cell culture comprising pancreatic cells, comprising the steps of a) contacting the cell culture comprising pancreatic cells with a DDR1 binding reagent;

and b) determining the quantity of cells that exhibit DDR1 as a cell surface marker (DDR1 positive cells).

8. The method of claim 7, wherein the number of DDR1 positive cells is periodically monitored.